Surgery: Current Research

ISSN - 2161-1076

How Dupixent has changed my life and the eczema community

Joint Event on International Conference on Plastic & Cosmetic Surgery & International Conference & Expo on Dermatopathology & Skin Care

August 31-September 01, 2018 | Toronto, Canada

Ashley Ann Lora

Dupixent Advocate in Los Angeles, USA

Posters & Accepted Abstracts: Surgery Curr Res

Abstract :

Dupixent is the first biological therapy approved by the FDA for adults suffering from moderate-to-severe atopic dermatitis (eczema). This new leading medication targets specific parts of the immune system that contributes to the inflammation found in many inflammatory conditions. It's biological component and healing from ???within??? make this injectable prescription medicine unique from other topical treatments like topical corticosteroids and immunosuppressant drugs. Studies of over 2100+ participants in Dupixent???s clinical trials have shown results in clearer skin and a significant reduction in itching. Ashley Lora was fortunate to be one of those participants and has experienced undeniable healing. With over 26 years of experience with moderate-to-severe atopic dermatitis, 15 years with asthma, and over 2 years of topical steroids withdrawal, Ashley is approximately 90% healed. Ashley???s experience with Dupixent since 2015 has given her an advantage in supporting others who need hope and are interested in Dupixent. Through her constant interaction with the eczema community, Ashley has compiled feedback from those currently on Dupixent. This will give others a better understanding of the patient perspective on what???s working and what is ineffective when it comes to this new therapy.

Biography :